

EKKYO and LLTech's research and development project on keloid scars has been approved.

Competitive clusters Eurobiomed and Optitec stamp their approval on EKKYO and LLTech R&D project to develop instrumentation to diagnose and treat keloid scars for the first time in the world.

MARSEILLE 25 MARCH 2009: EKKYO, a photomedicine company, which develops new assisted scarring tools first-in class laser-based systems for skin scar reduction and LLTech, a medical imaging company who develops equipment to make real time optic biopsies, have announced that their R&D project on keloid scars is supported by the competitive clusters Eurobiomed and Optitec and has been selected for financing following the public tender for research grant by the Fond Unique Interministériel (<http://www.competitivite.gouv.fr>).

Born out of a partnership between EKKYO, LLTech et l'Assistance Publique des Hôpitaux de Marseille (AP-HM), this collaborative project aims to establish itself as an international reference in treating these often incapacitating scars.

Each partner in the project plays a specific role in dealing with this pathology, from diagnostic to therapeutic :

- EKKYO, project leader, will be in charge of anticipating cicatricial complications and reducing mature scarring using a device deriving from EkkyLite™, a system that has demonstrated safety and efficacy to prevent and reduce scars.
- LLTECH is developing specific imaging instrumentation that enables non-invasive optic biopsies, i.e. tissue analysis (in depth and in real time) to differentiate (precociously and as follow up) healthy tissues in hypertrophic and keloid scars.
- AP-HM is carrying out keloid scar skin explants, heading up the clinical study and evaluating the solutions put forward by EKKYO and LLTech.

More information on www.ekkyo.fr and www.lltech.fr

Contact

Marielle BRICMAN
Managinf Director ATCG-Press
Mobile: +33 (0)6 26 94 18 53
mb@atcg-partners.com
or contact@lltech.fr